Clinical Cancer Research The Science of Cancer Health Disparities Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pappot, H.
Right arrow Articles by Osterlind, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pappot, H.
Right arrow Articles by Osterlind, K.

Clinical Cancer Research, Vol 2, Issue 1 155-160, Copyright © 1996 by American Association for Cancer Research


ARTICLES

p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis

H Pappot, D Francis, N Brunner, J Grondahl-Hansen and K Osterlind
The Finsen Laboratory and Department of Oncology, Rigshospitalet, DK-2100 Copenhagen, Denmark.

The prognostic value of p53 protein in tumor extracts as measured by ELISA was studied retrospectively in 228 non-small cell lung cancer (NSCLC) patients. The assay measures both wild-type and mutated p53. The specimens on which this study was performed have been used earlier to analyze the prognostic impact of components of the plasminogen activation system, which enabled an analysis of relationships between these components and p53 protein. The median of the p53 protein values in the 228 patients was 0.10 (range, 0-0.70) ng/mg protein. Survival analysis comparing patients with p53 levels below versus above the median showed no significant difference (P = 0.67). When analyzing the histological types, adenocarcinoma (n = 106), squamous cell carcinoma (n = 84), and large cell carcinoma of the lung (n = 38) separately, similarly, no significant differences in survival between patients having low versus high tumor p53 levels were found. When comparing levels of p53 protein in the three histological types, a significant difference (P < 0.0001) was found, with adenocarcinomas having the lowest levels. There was a weak positive correlation (r = 0.22) between p53 protein and plasminogen activator inhibitor type 1 (PAI-1). Multivariate analysis proved no impact of p53 on survival; tumor size, PAI-1, and lymph node involvement were the only variables with significant influence on survival. These data indicate that p53 protein quantitated with a sandwich ELISA in tumor extracts from NSCLC has no prognostic value, but the observed statistically significant difference of p53 protein content between histological subgroups may be related to differences in etiology and biology in different NSCLC subtypes. In addition, the weak association found between p53 protein and the independent prognostic marker PAI-1 could suggest yet undefined interactions in lung cancer.


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda
Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review
Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. D. Brundage, D. Davies, and W. J. Mackillop
Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress
Chest, September 1, 2002; 122(3): 1037 - 1057.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.P. Meert, F. Vallot, J.J. Lafitte, and J.P. Sculier
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
Eur. Respir. J., October 1, 2001; 18(4): 705 - 719.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. H. Schiller, S. Adak, R. H. Feins, S. M. Keller, W. A. Fry, R. B. Livingston, M. E. M. Hammond, B. Wolf, L. Sabatini, J. Jett, et al.
Lack of Prognostic Significance of p53 and K-ras Mutations in Primary Resected Non-Small-Cell Lung Cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy
J. Clin. Oncol., January 15, 2001; 19(2): 448 - 457.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Mitsudomi, N. Hamajima, M. Ogawa, and T. Takahashi
Prognostic Significance of p53 Alterations in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis
Clin. Cancer Res., October 1, 2000; 6(10): 4055 - 4063.
[Abstract] [Full Text]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. C. Tammemagi, J. R. McLaughlin, and S. B. Bull
Meta-Analyses of p53 Tumor Suppressor Gene Alterations and Clinicopathological Features in Resected Lung Cancers
Cancer Epidemiol. Biomarkers Prev., July 1, 1999; 8(7): 625 - 634.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1996 by the American Association for Cancer Research.